Conferences - Results from #9300

Viewing 9301-9320 of 11487 articles

EAU 2017: State-of-the-art Lecture: How will Immunotherapy Change the Treatment Paradigm?

EAU 2017: State-of-the-art Lecture: Is There Still a Role for Chemotherapy?

EAU 2017: Lymph node dissection is not associated with increased 30-day complication among patients undergoing radical nephrectomy for renal cell carcinoma: a propensity-score based analysis

EAU 2017: Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?

EAU 2017: Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)

EAU 2017: Familial and genetic factors: New SNPs and panels

EAU 2017: Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling

EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials

State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View

EAU 2017: State-of-the-art Lecture Immunotherapy: Impact from Oncologist’s Point of View

EAU 2017: A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

EAU 2017: First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

EAU 2017: A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

EAU 2017: Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy

EAU 2017: Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study

EAU 2017: A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)

EAU 2017: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study

EAU 2017: Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

EAU 2017: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

EAU 2017: Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

461
462
463
464
465
466
467
468
469
470